"11Three is disrupting the $635B chronic pain crisis with a patented, triple-action transdermal patch that provides 48-hour relief without the systemic side effects of opioids or oral meds. Backed by institutional validation from the University of Maryland and a 60,000-pharmacy distribution moat via CentennialRx, we are raising $5M to scale to a $78M revenue inflection."